

STIC-Biotech/ChemLib

116828

From: Hamud, Fozia  
Sent: Friday, March 12, 2004 4:29 PM  
To: STIC-Biotech/ChemLib  
Subject: sequence search for 09/997,514

Kindly search SEQ ID NO:422 of 09/997,514 against commercial and interference data bases. Thanks.

Fozia Hamud  
Patent Examiner  
Art Unit 1647  
Remsen, Room 4D64  
Mail Box Remsen-4C70  
272-0884

Searcher: \_\_\_\_\_  
Phone: \_\_\_\_\_  
Location: \_\_\_\_\_  
Date Picked Up: 3/15/04  
Date Completed: 3/15/04  
Searcher Prep/Review: \_\_\_\_\_  
Clerical: \_\_\_\_\_  
Online time: \_\_\_\_\_

TYPE OF SEARCH:  
NA Sequences: \_\_\_\_\_  
AA Sequences: 1  
Structures: \_\_\_\_\_  
Bibliographic: \_\_\_\_\_  
Litigation: \_\_\_\_\_  
Full text: \_\_\_\_\_  
Patent Family: \_\_\_\_\_  
Other: \_\_\_\_\_

VENDOR/COST (where applic.)  
STN: \_\_\_\_\_  
DIALOG: \_\_\_\_\_  
Questel/Orbit: \_\_\_\_\_  
DRLink: \_\_\_\_\_  
Lexis/Nexis: \_\_\_\_\_  
Sequence Sys.: asp  
WWW/Internet: \_\_\_\_\_  
Other (specify): \_\_\_\_\_

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: March 15, 2004, 08:27:54 ; Search time 58 seconds  
(without alignments)  
1919.374 Million cell updates/sec

Title: US-09-997-514-422

Perfect score: 2067  
Sequence: 1 MFPLKILPLVLDYSLG.....RNNSLKKSGGGMEXTQAP 394

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 1586107 seqs, 282547505 residues

Total number of hits satisfying chosen parameters: 1586107

Minimum DB seq length: 0  
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : A\_Geneseq\_29Jan04:\*  
1: geneseqp1980s:\*  
2: geneseqp1990s:\*  
3: geneseqp2000s:\*  
4: geneseqp2001s:\*  
5: geneseqp2002s:\*  
6: geneseqp2003as:\*  
7: geneseqp2003bs:\*  
8: geneseqp2004s:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	2067	100.0	394	AAV66764	AAV66764 Membrane-
2	2067	100.0	394	AB33454	AB33454 Human PRO
3	2067	100.0	394	AAV94452	AAV94452 Human inf
4	2067	100.0	394	AB24433	AB24433 Human PRO
5	2067	100.0	394	AAU12431	AAU12431 Human PRO
6	2067	100.0	394	AAV38860	AAV38860 Human pol
7	2067	100.0	394	AAV5287	AAV5287 Human PRO
8	2067	100.0	394	AAU83689	AAU83689 Human PRO
9	2067	100.0	394	AB84933	AB84933 Human PRO
10	2067	100.0	394	AB95539	AB95539 Human ang
11	2067	100.0	394	ABU58102	ABU58102 Human PRO
12	2067	100.0	394	ABU59180	ABU59180 Novel hum
13	2067	100.0	394	ABU82692	ABU82692 Human sec
14	2067	100.0	394	ABU17875	ABU17875 Novel hum
15	2067	100.0	394	ABU60611	ABU60611 Human sec
16	2067	100.0	394	ABU80836	ABU80836 Human PRO
17	2067	100.0	394	ABU33802	ABU33802 Novel hum
18	2067	100.0	394	ABU13993	ABU13993 Human PRO
19	2067	100.0	394	ABU81129	ABU81129 Human PRO
20	2067	100.0	394	ABU72578	ABU72578 Novel hum
21	2067	100.0	394	ABU66829	ABU66829 Human PRO
22	2067	100.0	394	ABU59910	ABU59910 Novel sec
23	2067	100.0	394	ABU59327	ABU59327 Human sec
24	2067	100.0	394	ABU26024	ABU26024 Human PRO
25	2067	100.0	394	ABO25100	ABO25100 Human sec

26	2067	100.0	394	ABU82145	ABU82145 Novel hum
27	2067	100.0	394	ABU59033	ABU59033 Human sec
28	2067	100.0	394	ABU92411	ABU92411 Novel hum
29	2067	100.0	394	ABU59476	ABU59476 Novel hum
30	2067	100.0	394	ABU67105	ABU67105 Human sec
31	2067	100.0	394	ABU92242	ABU92242 Novel hum
32	2067	100.0	394	ABU10948	ABU10948 Human PRO
33	2067	100.0	394	ABU81700	ABU81700 Novel hum
34	2067	100.0	394	ABU86639	ABU86639 Human sec
35	2067	100.0	394	ABO34153	ABO34153 Human PRO
36	2067	100.0	394	ADA46039	ADA46039 Novel hum
37	2067	100.0	394	ADA76470	ADA76470 Human PRO
38	2067	100.0	394	ABU72325	ABU72325 Human PRO
39	2067	100.0	394	ADA19120	ADA19120 Human PRO
40	2067	100.0	394	ADA61743	ADA61743 Homo sapi
41	2067	100.0	394	ADA19528	ADA19528 Novel hum
42	2067	100.0	394	ADA28069	ADA28069 Human PRO
43	2067	100.0	394	ADA86548	ADA86548 Novel hum
44	2067	100.0	394	ADA16112	ADA16112 Human PRO
45	2067	100.0	394	ADA37933	ADA37933 Human sec

## ALIGNMENTS

RESULT 1	AAV66764 standard; protein; 394 AA.
ID	AAV66764
AC	AAV66764;
DT	05-APR-2000 (first entry)
XX	Membrane-bound protein PRO1387.
DE	Membrane-bound polypeptide; PRO polypeptide; LDL receptor; TIE ligand;
XX	pharmaceutical; receptor immunoadhesin; gene mapping.
XX	Homo sapiens.
OS	Homo sapiens.
XX	MO9963088-A2.
PN	MO9963088-A2.
XX	09-DEC-1999.
PD	09-DEC-1999.
XX	02-JUN-1999;
PF	99MO-US012252.
XX	02-JUN-1998;
PR	98US-0087607P.
PR	02-JUN-1998;
PR	98US-0087609P.
PR	02-JUN-1998;
PR	98US-0087759P.
PR	03-JUN-1998;
PR	98US-0087827P.
PR	04-JUN-1998;
PR	98US-0088021P.
PR	04-JUN-1998;
PR	98US-0088025P.
PR	04-JUN-1998;
PR	98US-0088028P.
PR	04-JUN-1998;
PR	98US-0088029P.
PR	04-JUN-1998;
PR	98US-0088030P.
PR	04-JUN-1998;
PR	98US-0088033P.
PR	04-JUN-1998;
PR	98US-0088036P.
PR	05-JUN-1998;
PR	98US-0088167P.
PR	05-JUN-1998;
PR	98US-0088202P.
PR	05-JUN-1998;
PR	98US-0088217P.
PR	05-JUN-1998;
PR	98US-0088219P.
PR	09-JUN-1998;
PR	98US-0088655P.
PR	10-JUN-1998;
PR	98US-0088722P.
PR	10-JUN-1998;
PR	98US-0088730P.
PR	10-JUN-1998;
PR	98US-0088734P.
PR	10-JUN-1998;
PR	98US-0088738P.
PR	10-JUN-1998;
PR	98US-0088740P.
PR	10-JUN-1998;
PR	98US-0088741P.
PR	10-JUN-1998;
PR	98US-0088742P.
PR	10-JUN-1998;
PR	98US-0088810P.
PR	10-JUN-1998;
PR	98US-0088811P.
PR	10-JUN-1998;
PR	98US-0088824P.
PR	10-JUN-1998;
PR	98US-0088825P.

Sequence comparison





# Sequence Comparison

QY 61 PGBHAKDEYLYYYNSLSPVIGRPNRHHMDIICNGSLILDVQEAQGTTCIRL 120  
 DB 61 PGBHAKDEYLYYYNSLSPVIGRPNRHHMDIICNGSLILDVQEAQGTTCIRL 120  
 OY 121 KESQVFKKAVVLYHLPFEEKELMAYVGLILMGCVFQSTVEKATYKEMIFSGRAKEE 180  
 DB 121 KESQVFKKAVVLYHLPFEEKELMAYVGLILMGCVFQSTVEKATYKEMIFSGRAKEE 180  
 OY 181 IYPRYHKLKRMVEYSQSGHGFQNRVNLVGDIFRDGSLIMQVRESGQYITCSHILGN 240  
 DB 181 IYPRYHKLKRMVEYSQSGHGFQNRVNLVGDIFRDGSLIMQVRESGQYITCSHILGN 240  
 OY 241 LVFKKTIYLVHSPPEERLTVPALRPVLVGNQVLIIVGIVCATIILLPVLIIIVKTC 300  
 DB 241 LVFKKTIYLVHSPPEERLTVPALRPVLVGNQVLIIVGIVCATIILLPVLIIIVKTC 300  
 OY 301 GKSSVNSTVLYVNTKNTPEIKERPCFERGEGEKHLYSPILYREVIIEEPESEKSEAT 360  
 DB 301 GKSSVNSTVLYVNTKNTPEIKERPCFERGEGEKHLYSPILYREVIIEEPESEKSEAT 360  
 OY 361 YMTMPVMPSLSDRNNSLEKSGGGMPTQCAF 394  
 DB 361 YMTMPVMPSLSDRNNSLEKSGGGMPTQCAF 394

AAB33454  
 ID AAB33454 standard; protein; 394 AA.  
 AC AAB33454;  
 XX  
 DT 29-JAN-2001 (first entry)  
 XX  
 DE Human PRO1387 protein UNQ722 SEQ ID NO:187.  
 XX  
 KW Human; immune related disease; diagnosis; antiinflammatory; cardiant;  
 KW dermatological; antihypertic; antirheumatic; immunosuppressive;  
 KW haemostatic; antidiabetic; nocotropic; neuroprotective;  
 KW antineumatic; hepatotropic; vitruice; antipsoriatic; antiallergic;  
 KW antiscarific; systemic lupus erythematosus; rheumatoid arthritis;  
 KW idiopathic inflammatory myopathy; Sjogren's syndrome; thyroiditis;  
 KW systemic vasculitis; autoimmune haemolytic anaemia; diabetes mellitus;  
 KW autoimmune thrombocytopenia; immune-mediated renal disease;  
 KW demyelinating disease; hepatobiliary disease; Whipple's disease;  
 KW inflammatory bowel disease; gluten-sensitive enteropathy;  
 KW autoimmune disease; immune-mediated skin disease; allergic disease;  
 KW immunological disease; transplantion associated disease;  
 KW graft rejection; graft-versus-host-disease.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200053758-A2.  
 XX  
 PD 14-SEP-2000.  
 XX  
 PF 02-MAR-2000; 2000WO-US005841.  
 XX  
 XX 08-MAR-1999; 99WO-US005028.  
 PR 10-MAR-1999; 99US-0123618P.  
 PR 12-MAR-1999; 99US-0123957P.  
 PR 23-MAR-1999; 99US-0125775P.  
 PR 12-APR-1999; 99US-0128849P.  
 PR 20-APR-1999; 99WO-US006615.  
 PR 28-APR-1999; 99US-0131445P.  
 PR 04-MAY-1999; 99US-0132371P.  
 PR 14-MAY-1999; 99US-0134287P.  
 PR 02-JUN-1999; 99WO-US012252.  
 PR 23-JUN-1999; 99US-0141037P.  
 PR 26-JUL-1999; 99US-0144758P.  
 PR 28-JUL-1999; 99US-0145698P.  
 PR 28-JUL-1999; 99US-0146222P.

PR 01-SEP-1999; 99WO-US020111.  
 PR 08-SEP-1999; 99WO-US020594.  
 PR 13-SEP-1999; 99WO-US020944.  
 PR 15-SEP-1999; 99WO-US021047.  
 PR 15-SEP-1999; 99WO-US021547.  
 PR 05-OCT-1999; 99WO-US023089.  
 PR 29-OCT-1999; 99US-0162506P.  
 PR 29-NOV-1999; 99WO-US028214.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 30-NOV-1999; 99WO-US028409.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 01-DEC-1999; 99WO-US028634.  
 PR 02-DEC-1999; 99WO-US028551.  
 PR 02-DEC-1999; 99WO-US028564.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030399.  
 PR 30-DEC-1999; 99WO-US031274.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 06-JAN-2000; 2000WO-US000277.  
 PR 06-JAN-2000; 2000WO-US000376.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 18-FEB-2000; 2000WO-US004341.  
 PR 18-FEB-2000; 2000WO-US004342.  
 PR 22-FEB-2000; 2000WO-US004414.  
 XX  
 XX (GETH ) GENENTECH INC.  
 XX  
 PA Ashkenazi AJ, Baker KP, Goddard A, Gurney AL, Hebert C, Henzel W,  
 PI Kabakoff RC, Lu Y, Pan J, Pennica D, Shelton DL, Smith V,  
 PI Stewart TA, Tamas D, Watanabe CK, Wood WI, Yan M,  
 XX WPI: 2000-572271/53.  
 DR N-PSDB; AAC58619.  
 DR  
 XX  
 PT Sixty four PRO polypeptides, useful in the diagnosis and treatment of  
 PT immune related disorders, e.g. systemic lupus erythematosus, rheumatoid  
 PT arthritis, osteoarthritis, thyroiditis and diabetes mellitus.  
 XX  
 XX Claim 33, Fig 82; 309pp; English.  
 XX  
 XX The present invention describes sixty four human PRO proteins which can  
 XX be used in the treatment of immune related diseases. The human PRO  
 XX proteins, anti-PRO antibodies, agonists and antagonists are useful for  
 XX treating and diagnosing immune related disorders. The disorders are  
 XX selected from systemic lupus erythematosus, rheumatoid arthritis,  
 XX osteoarthritis, juvenile chronic arthritis, spondyloarthropathies,  
 XX systemic sclerosis, idiopathic inflammatory myopathies, Sjogren's  
 XX syndrome, systemic vasculitis, sarcoidosis, autoimmune haemolytic  
 XX anaemia, autoimmune thrombocytopenia, thyroiditis, diabetes mellitus,  
 XX immune-mediated renal disease, demyelinating diseases of the central and  
 XX peripheral nervous systems, hepatobiliary diseases, inflammatory bowel  
 XX disease, gluten-sensitive enteropathy and Whipple's disease, autoimmune  
 XX or immune-mediated skin diseases, allergic diseases, immunological  
 XX diseases of the lung, and transplantation associated diseases including  
 XX graft rejection and graft-versus-host-disease. AAC58397 to AAC58578  
 XX represent PCR primers and hybridisation probes used in the isolation of  
 XX human PRO sequences. AAC58579 to AAC58642 and MA33414 to AAB334477  
 XX represent human PRO polynucleotide and protein sequences given in the  
 XX exemplification of the present invention

SO Sequence 394 AA;  
 Query Match 100.0%; Score 2067; DB 3; Length 394;  
 Best Local Similarity 100.0%; Pred. No. 5,1e-188;  
 Matches 394; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 OY 1 MFCEPKLILPVLVDYSGINDLVSPPELTIVHVGDSALMGCVFQSTBEDKICIKIMPTTS 60  
 DB 1 MFCEPKLILPVLVDYSGINDLVSPPELTIVHVGDSALMGCVFQSTBEDKICIKIMPTTS 60  
 OY 61 PGBHAKDEYLYYYNSLSPVIGRPNRHHMDIICNGSLILDVQEAQGTTCIRL 120

DB 61 PGEHAKDEVLVLYYNSLSVPIGRFQNRVHLMGDIICNDGSLLDVQADQGTICIRL 120  
 QY 121 KGESQVFKKAVLVHLVPEEPKELMVAHGLIQGCVFQSTEVKHTKVMIFSGRAKEE 180  
 DB 121 KGESQVFKKAVLVHLVPEEPKELMVAHGLIQGCVFQSTEVKHTKVMIFSGRAKEE 180  
 QY 181 IYFRYYHKLMSVEYSQSGHGFQNRVNLVGDIFRNDGSLMLQGVRESQGNVTCSTHLEN 240  
 DB 181 IYFRYYHKLMSVEYSQSGHGFQNRVNLVGDIFRNDGSLMLQGVRESQGNVTCSTHLEN 240  
 QY 241 LVFKKTIIVLHVSPEEPRTLVTPALRPVLVAGNQLVIVGIVCATILLPVLLIVKTC 300  
 DB 241 LVFKKTIIVLHVSPEEPRTLVTPALRPVLVAGNQLVIVGIVCATILLPVLLIVKTC 300  
 QY 301 GKSSVNSTVLVKNKTKNPEIKERPCFERCEGEGHIVSPITVREVIIEEPESEKSEAT 360  
 DB 301 GKSSVNSTVLVKNKTKNPEIKERPCFERCEGEGHIVSPITVREVIIEEPESEKSEAT 360  
 QY 361 YMTMHPVWPSLRSDRNNSLKSGGMPKTOQAF 394  
 DB 361 YMTMHPVWPSLRSDRNNSLKSGGMPKTOQAF 394

RESULT 3  
 AAY94452  
 ID AAY94452 standard; protein; 394 AA.  
 AC AAY94452;

DT 11-SEP-2000 (first entry)  
 XX Human inflammation associated protein #11.  
 DE Inflammation; rheumatoid arthritis; Crohn's disease; asthma;  
 KM multiple sclerosis; allergy; AIDS; diabetes mellitus antinflammatory;  
 KW gene therapy; human.

OS Homo sapiens.  
 XX WO200029574-A2.  
 PN 25-MAY-2000.  
 PD 04-NOV-1999; 99WO-US026234.  
 PF 18-NOV-1998; 98US-00195292.  
 PR (INCY-) INCYTE PHARM INC.  
 PA Walker MG, Volkmut W, Klingler TM;  
 PI WPI, 2000-38787/33.  
 DR N-PSDB; AAA27133.  
 XX New human inflammation-associated polypeptide useful for diagnosis,  
 PT prevention and treatment of inflammatory diseases comprises product of  
 PT gene coexpressed with e.g. CD1e, L-selectin and IP-30.  
 PS Claim 4; Page 42-43; 43pp; English.

CC Eleven novel inflammation-associated genes have been identified in cDNA  
 CC libraries from various tissues. The genes were selected according to  
 CC their coexpression with the known inflammation genes, CD1e, L-selectin,  
 CC Src-like adapter protein, IP-30, superoxide homoenzyme subunits, alpha-  
 CC 1-antitrypsin, C1q-A, 5-lipoxygenase activating protein and SRC family  
 CC tyrosine kinase. The novel polynucleotides may be used in hybridization  
 CC assays to diagnose a disease or condition associated with altered  
 CC expression of the inflammation genes. Antibodies against the genes may be  
 CC useful in compositions for the diagnosis and treatment of such diseases  
 CC associated with inflammation including rheumatoid arthritis, Crohn's  
 CC disease, multiple sclerosis, AIDS, diabetes mellitus, asthma and allergy.  
 CC Additionally the polynucleotides of the invention may be used for gene  
 CC therapy. The present sequence is human inflammation associated protein

CC #11, derived from Incyte Clone 3507924  
 XX Sequence 394 AA;  
 SQ Query Match 100.0%; Score 2067; DB 3; Length 394;  
 Best Local Similarity 100.0%; Pred. No. 5,1e-188;  
 Matches 394; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MFCPLKILLPVLLDLSGLINDLVNPPPELTVHVGDSALMGCVFQSTEDKCFKIDWTIS 60  
 DB 1 MFCPLKILLPVLLDLSGLINDLVNPPPELTVHVGDSALMGCVFQSTEDKCFKIDWTIS 60  
 QY 61 PGEHAKDEVLVLYYNSLSVPIGRFQNRVHLMGDIICNDGSLLDVQADQGTICIRL 120  
 DB 61 PGEHAKDEVLVLYYNSLSVPIGRFQNRVHLMGDIICNDGSLLDVQADQGTICIRL 120  
 QY 121 KGESQVFKKAVLVHLVPEEPKELMVAHGLIQGCVFQSTEVKHTKVMIFSGRAKEE 180  
 DB 121 KGESQVFKKAVLVHLVPEEPKELMVAHGLIQGCVFQSTEVKHTKVMIFSGRAKEE 180  
 QY 181 IYFRYYHKLMSVEYSQSGHGFQNRVNLVGDIFRNDGSLMLQGVRESQGNVTCSTHLEN 240  
 DB 181 IYFRYYHKLMSVEYSQSGHGFQNRVNLVGDIFRNDGSLMLQGVRESQGNVTCSTHLEN 240  
 QY 241 LVFKKTIIVLHVSPEEPRTLVTPALRPVLVAGNQLVIVGIVCATILLPVLLIVKTC 300  
 DB 241 LVFKKTIIVLHVSPEEPRTLVTPALRPVLVAGNQLVIVGIVCATILLPVLLIVKTC 300  
 QY 301 GKSSVNSTVLVKNKTKNPEIKERPCFERCEGEGHIVSPITVREVIIEEPESEKSEAT 360  
 DB 301 GKSSVNSTVLVKNKTKNPEIKERPCFERCEGEGHIVSPITVREVIIEEPESEKSEAT 360  
 QY 361 YMTMHPVWPSLRSDRNNSLKSGGMPKTOQAF 394  
 DB 361 YMTMHPVWPSLRSDRNNSLKSGGMPKTOQAF 394

RESULT 4  
 AAB24433  
 ID AAB24433 standard; protein; 394 AA.

AC AAB24433;  
 DT 07-NOV-2000 (first entry)

DE Human PRO1387 protein sequence SEQ ID NO:220.

KM Human; PRO; promotion; inhibition; angiogenesis; cardiovascularization;  
 KW diagnosis; trauma; wound; cancer; atherosclerosis; cardiac hypertrophy;  
 KW angiogenic; proliferative; cardiant; cardiovascular; antiatherosclerotic;  
 KW cyostatic; gene therapy; vaccine.

OS Homo sapiens.  
 XX WO200032221-A2.  
 PN 08-JUN-2000.  
 PD 30-NOV-1999; 99WO-US028313.  
 PF 01-DEC-1998; 98WO-US025108.  
 PR 16-DEC-1998; 98US-0112850P.  
 PR 12-JUN-1999; 99US-0115554P.  
 PR 08-MAR-1999; 99WO-US005028.  
 PR 12-MAR-1999; 99US-0123957P.  
 PR 28-APR-1999; 99US-0131445P.  
 PR 14-MAY-1999; 99US-0134287P.  
 PR 02-JUN-1999; 99WO-US012252.  
 PR 23-JUN-1999; 99US-0141037P.  
 PR 20-JUL-1999; 99US-0144758P.  
 PR 26-JUL-1999; 99US-0145698P.  
 PR 01-SEP-1999; 99WO-US020111.  
 PR 08-SEP-1999; 99WO-US020594.

sequence  
 TB, Capri 500

# Sequence Comparison

PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-OCT-1999; 99US-0162506P.

XX (GENTH ) GENENTECH INC.

PA Ashkenazi AJ, Baker KP, Ferrara N, Gerber H, Hillan KJ,  
PI Goddard A, Godowski PJ, Gueney AL, Klein RD, Kuo SS, Paoni NF,  
PI Smith V, Watanabe CK, Williams PM, Wood WI;  
XX MPI; 2000-412154/35.  
DR N-PSDB; AA477683.

PT Nucleic acids encoding PRO polypeptides useful for preventing, diagnosing  
PT and creating a diagnosis a cardiovascular, endothelial or angiogenic  
PT disorders in mammals.

PS Claim 72; Fig 92; 315pp; English.

XX The present invention describes nucleic acids encoding PRO polypeptides  
CC useful for preventing, diagnosing and treating disorders in mammals by  
CC cardiovascular, endothelial or angiogenic disorder in mammals by  
CC modulating cell proliferation, angiogenesis and cardiovascularisation,  
CC and for identifying agonists and antagonists of these processes. The  
CC nucleic acids and the proteins they encode may be used in the prevention,  
CC treatment and diagnosis of diseases associated with inappropriate PRO  
CC expression such as cardiovascular, endothelial or angiogenic disorders in  
CC mammals (e.g. atherosclerosis, cancers and cardiac hypertrophy). For  
CC example, the nucleic acids (NAs) and vectors containing them and the PRO  
CC polypeptide may be used to treat disorders associated with decreased PRO  
CC expression. AA477510 to AA477721 and AA42438 to AA42435 represent  
CC nucleotide and protein sequences used in the exemplification of the  
CC present invention

SO Sequence 394 AA:

Query Match 100.0%; Score 2067; DB 3; Length 394;  
Best Local Similarity 100.0%; Fred. No. 5.1e-188;  
Matches 394; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MFCPLNLLPVLIDYSLGNDLANSPELTVHVDASALMGCVFQSTEDKCFKIDWTLS 60  
DB 1 MFCPLNLLPVLIDYSLGNDLANSPELTVHVDASALMGCVFQSTEDKCFKIDWTLS 60  
QY 61 PGHACDEYVLYYSNLSVIFGRFQNRVHMGDILCNDSGLLDVQDAOGTICIRL 120  
DB 61 PGHACDEYVLYYSNLSVIFGRFQNRVHMGDILCNDSGLLDVQDAOGTICIRL 120  
QY 121 KGSQYFKKAVVLAHVPPEPKELMHVGLIOMGCVFQSTEDKCFKIDWTLS 180  
DB 121 KGSQYFKKAVVLAHVPPEPKELMHVGLIOMGCVFQSTEDKCFKIDWTLS 180  
QY 181 IYFRYHKLKMSVEYSQSGHQRNRYVYDIFRDSIMQVRESGGVYTSIHLGN 240  
DB 181 IYFRYHKLKMSVEYSQSGHQRNRYVYDIFRDSIMQVRESGGVYTSIHLGN 240  
QY 241 LVFRKTIIVHVSPEEPRITVTPALRPLVLAGNOLVIVGICATILLPVLIIIVKTC 300  
DB 241 LVFRKTIIVHVSPEEPRITVTPALRPLVLAGNOLVIVGICATILLPVLIIIVKTC 300  
QY 301 GNKSSVNSTVLVNTKTNPEIKRCPHRCCEGKHIYSPIVREVEEPESEKSEAT 360  
DB 301 GNKSSVNSTVLVNTKTNPEIKRCPHRCCEGKHIYSPIVREVEEPESEKSEAT 360  
QY 361 YMTMHPVPSLRSDRNLSLEKSGGGMPTQOAF 394  
DB 361 YMTMHPVPSLRSDRNLSLEKSGGGMPTQOAF 394

RESULT 5  
AAU12431

ID AAU12431 standard; protein; 394 AA.

XX AAU12431;

AC AAU12431;

XX 24-OCT-2001 (first entry)

DT Human PRO1387 polypeptide sequence.

XX Human secretory and transmembrane; PRO; mammalian; cancer; lung; breast;  
XX prostate; cervical; tumour necrosis factor-alpha; TNF-alpha; cartilage;  
XX ear; proliferation; tumour; free fatty acid; skeletal muscle; adipocyte;  
XX A-peptide; factor VIIa; gene therapy.

OS Homo sapiens.

XX MO200140466-A2.

XX 07-JUN-2001.

XX 01-DEC-2000; 2000WO-US032678.

XX 01-DEC-1999; 99WO-US028301.

XX 01-DEC-1999; 99WO-US028634.

XX 02-DEC-1999; 99WO-US028651.

XX 02-DEC-1999; 99WO-US028664.

XX 02-DEC-1999; 99WO-US028665.

XX 09-DEC-1999; 99US-0170262F.

XX 15-DEC-1999; 99WO-US030095.

XX 20-DEC-1999; 99WO-US030911.

XX 30-DEC-1999; 99WO-US030999.

XX 30-DEC-1999; 99WO-US031274.

XX 05-JAN-2000; 2000WO-US000219.

XX 06-JAN-2000; 2000WO-US000277.

XX 11-FEB-2000; 2000WO-US000376.

XX 18-FEB-2000; 2000WO-US000434.

XX 22-FEB-2000; 2000WO-US000442.

XX 24-FEB-2000; 2000WO-US000494.

XX 24-FEB-2000; 2000WO-US000504.

XX 01-MAR-2000; 2000WO-US000501.

XX 02-MAR-2000; 2000WO-US000541.

XX 03-MAR-2000; 2000US-0187202P.

XX 10-MAR-2000; 2000WO-US006319.

XX 15-MAR-2000; 2000WO-US006884.

XX 20-MAR-2000; 2000WO-US007377.

XX 21-MAR-2000; 2000WO-US007377.

XX 30-MAR-2000; 2000WO-US008439.

XX 17-MAY-2000; 2000WO-US013705.

XX 22-MAY-2000; 2000WO-US014042.

XX 30-MAY-2000; 2000WO-US014941.

XX 02-JUN-2000; 2000WO-US015264.

XX 05-JUN-2000; 2000US-0209832P.

XX 28-JUL-2000; 2000WO-US0220710.

XX 11-AUG-2000; 2000WO-US0220710.

XX 23-AUG-2000; 2000WO-US023522.

XX 24-AUG-2000; 2000WO-US023328.

XX 08-NOV-2000; 2000WO-US030952.

XX 10-NOV-2000; 2000WO-US030873.

(GENTH ) GENENTECH INC.

PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W,  
PI Gerlitsen ME, Goddard A, Godowski PJ, Gueney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX MPI; 2001-408281/43.  
XX N-PSDB; AA521503.

PT Isolated, secretory and transmembrane PRO polypeptide used to detect  
PT other PRO polypeptides, link bioactive molecules to cells expressing PRO  
PT polypeptides, and detect the presence of mammalian tumors e.g. lung,

Db	61	PGHBADEYLVYYYSNLSPVIGRFQNRVHMLDILCNDGSLLDQVDEAOGYTICEL	120
QY	121	KGESQVFKKAVLHVLPSPKELMHWGGLIMQGVCFPOSTEKVHTVKEVIFSGRAKE	180
Db	121	KGESQVFKKAVLHVLPSPKELMHWGGLIMQGVCFPOSTEKVHTVKEWIFSGRAKE	180
QY	181	IVERYHKLMSVETYSQSMGFQNRVNLGDFRNDGSIIMQGVRESGNGYTSIHLGN	240
Db	181	IVERYHKLMSVETYSQSMGFQNRVNLGDFRNDGSIIMQGVRESGNGYTSIHLGN	240
QY	241	LVFKKTIIVLHVSSEERTLVTPAALRPVLVGGNQLVTVGVCAITLLPYLLIVKTC	300
Db	241	LVFKKTIIVLHVSSEERTLVTPAALRPVLVGGNQLVTVGVCAITLLPYLLIVKTC	300
QY	301	GKNSVNSITLVNNTTKTNPEIKKCFHRCGESEKHLYSPILVREVLIEEHPSEKEAT	360
Db	301	GKNSVNSITLVNNTTKTNPEIKKCFHRCGESEKHLYSPILVREVLIEEHPSEKEAT	360
QY	361	YMTHEPVMPSLRSDRNLSLEKSGGGMPTQOAF	394
Db	361	YMTHEPVMPSLRSDRNLSLEKSGGGMPTQOAF	394

sequence comparison

RESULT 3
AA194452
ID AA194452 standard; protein; 394 AA.
XX
XX AA194452;
XX AC
XX 11-SEP-2000 (first entry)
XX
XX Human inflammation associated protein #11.
XX
KW Inflammation; rheumatoid arthritis; Crohn's disease; asthma;
KW multiple sclerosis; allergy; AIDS; diabetes mellitus antinflammatory;
KW gene therapy; human.
XX
OS Homo sapiens.
XX
XX MO200029574-A2.
XX
XX 25-MAY-2000.
XX
XX 04-NOV-1999; 99MO-USC6234.
XX
XX 18-NOV-1998; 98US-00195292.
XX
XX (INCY-) INCYTE PHARM INC.
XX
XX Walker MG, Volkmueth W, Klingler TM;
XX
XX WPI: 2000-387787/33.
XX
XX N-PSDB; AAA27133.
XX
XX New human inflammation-associated polypeptide useful for diagnosis,
XX prevention and treatment of inflammatory diseases comprises product of
XX gene coexpressed with e.g. CD16, L-selectin and IP-30.

Claim 4; Page 42-43; 43pp; English.

Eleven gene inflammation-associated genes have been identified in cDNA libraries from various tissues. The genes were selected according to their coexpression with the known inflammation genes, CD66, *I*-selectin, Src-like adapter protein, *I*p-30, superoxide dismutase, xanthine oxidase, 1-antitrypsin, C1qA, 5-lipoxygenase activating protein and SRC family tyrosine kinase. The novel polymorphonuclears may be used in hybridization assays to diagnose a disease or condition associated with altered expression of the inflammation genes. Antibodies against the genes may be useful in compositions for the diagnosis and treatment of such diseases associated with inflammation including rheumatoid arthritis, Crohn's disease, multiple sclerosis, AIDS, diabetes mellitus, asthma and allergy. Additionally the polymorphonuclears of the invention may be used for gene therapy. The present sequence is human inflammation associated protein

CC	#11, derived from Incyte Clone 3507924	
XX		
5Q	Sequence 394 AB;	
	Query Match	100.0%; Score 2067; DB 3; Length 394;
	Ident. Local Similarity	100.0%; P-Id. No. 5,1e-188;
	Matches 394; Conservative	0; Mismatches 0; Indels 0; Gaps 0

QY	1	MFCEPLKILLPLVLDLUSGLNDLVNSPEELIVHNGSALMGCVFOSREBKCFKIDWNTLS	60
Dd	1	MFCEPLKILLPLVLDLUSGLNDLVNSPEELIVHNGSALMGCVFOSREBKCFKIDWNTLS	60
QY	61	PGSHAKDEYLVLYYSNLSVPTRGFQNRVHLMGDILCNDGSLILDDYQDADQCTYICEITL	120
Dd	61	PGSHAKDEYLVLYYSNLSVPTRGFQNRVHLMGDILCNDGSLILDDYQDADQCTYICEITL	120
QY	121	KGSQYCFKAAVVLVHLPEPEKELMWHVVGILLQMCVCVQSTEVHAKVKEWIFSGRAKAE	180
Dd	121	KGSQYCFKAAVVLVHLPEPEKELMWHVVGILLQMCVCVQSTEVHAKVKEWIFSGRAKAE	180
QY	181	IYFRYTHKLKMSVEISQSWGHFORNVNLVEDIFPNDGSLMLQCYRSDGNTYCSHLGN	240
Dd	181	IYFRYTHKLKMSVEISQSWGHFORNVNLVEDIFPNDGSLMLQCYRSDGNTYCSHLGN	240
QY	241	LVEFKTITVLHVSFEERPLTVLPALRPLVVGNOVLIVIVGATILLPVLLIVKTKC	300
Dd	241	LVEFKTITVLHVSFEERPLTVLPALRPLVVGNOVLIVIVGATILLPVLLIVKTKC	300
QY	301	GKMSSTNSVIVKTKNPETIKKCPCHFECESEKTIYPIIVREYIEEBSSEKSEAT	360
Dd	301	GKMSSTNSVIVKTKNPETIKKCPCHFECESEKTIYPIIVREYIEEBSSEKSEAT	360
QY	361	YMTMHFVWPSLSRSDRNSLEKKSQGGMPKTDQAF	394
Dd	361	YMTMHFVWPSLSRSDRNSLEKKSQGGMPKTDQAF	394

RESULT 4	
AAB24433	
ID	AAB24433 standard; protein; 394 AA.
AC	
XX	AAB24433;
XX	
DT	07-NOV-2000 (first entry)
DE	
XX	Human Prol387 protein sequence SEQ ID NO:220.
KM	Human; P/O, promotion; inhibition; angiogenesis; cardiovascularization;
KM	diagnosis; trauma wound; cancer; atherosclerosis; cardiac hypertrophy;
KM	angiogenic; proliferative; cardiac; cardiovascular; atherosclerotic;
XX	cytostatic; gene therapy; vaccine.
OS	Homo sapiens.
PN	WO200032221-A2.
XX	
ED	08-JUN-2000.
XX	
PF	30-NOV-1999; 99WO-US028313.
XX	
PR	01-DEC-1998; 98WO-US025108.
PR	16-DEC-1998; 98US-0112850P.
PR	12-JAN-1999; 99US-0115542P.
PR	08-MAR-1999; 99WO-US005028.
PR	12-MAR-1999; 99US-0123957P.
PR	26-APR-1999; 99US-0131445P.
PR	14-MAY-1999; 99US-0134287P.
PR	02-JUN-1999; 99WO-US012252.
PR	23-JUN-1999; 99US-0141037P.
PR	20-JUL-1999; 99US-0144758P.
PR	26-JUL-1999; 99US-0145696P.
PR	01-SEP-1999; 99WO-US020111.
PR	08-SEP-1999; 99WO-US020594.